Ultragenyx Pharmaceutical Management
Management criteria checks 2/4
Ultragenyx Pharmaceutical's CEO is Emil Kakkis, appointed in Apr 2010, has a tenure of 14.42 years. total yearly compensation is $13.08M, comprised of 6.3% salary and 93.7% bonuses, including company stock and options. directly owns 2.92% of the company’s shares, worth $148.26M. The average tenure of the management team and the board of directors is 8.7 years and 8.4 years respectively.
Key information
Emil Kakkis
Chief executive officer
US$13.1m
Total compensation
| CEO salary percentage | 6.3% |
| CEO tenure | 14.4yrs |
| CEO ownership | 2.9% |
| Management average tenure | 8.7yrs |
| Board average tenure | 8.4yrs |
Recent management updates
Recent updates
We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt
Sep 04
Ultragenyx's Strong Pipeline And Valuation Concerns: A Balanced Perspective
Aug 22There's Reason For Concern Over Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Massive 26% Price Jump
Aug 03Shareholders Will Probably Hold Off On Increasing Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) CEO Compensation For The Time Being
Jun 12Ultragenyx: Modest Sales Growth, With Multiple Inflection Points Approaching
Jun 06We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt
May 24Ultragenyx Pharmaceutical Earnings: No Visible Path To Financial Success Yet
Mar 09Will Ultragenyx Pharmaceutical (NASDAQ:RARE) Spend Its Cash Wisely?
Feb 01There's No Escaping Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Muted Revenues Despite A 28% Share Price Rise
Dec 28Is There An Opportunity With Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) 47% Undervaluation?
Sep 12An Intrinsic Calculation For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Suggests It's 50% Undervalued
May 24Improved Revenues Required Before Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Find Their Feet
Apr 17Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Could Be 33% Below Their Intrinsic Value Estimate
Feb 18Ultragenyx upgraded to buy at Guggenheim as stock trading at discount to biotech peers
Oct 13Ultragenyx grants stock options, restricted stock units
Oct 05Ultragenyx Pharmaceuticals: Downward Trajectory Likely To Continue
Sep 02CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$585m |
| Mar 31 2024 | n/a | n/a | -US$613m |
| Dec 31 2023 | US$13m | US$824k | -US$607m |
| Sep 30 2023 | n/a | n/a | -US$635m |
| Jun 30 2023 | n/a | n/a | -US$721m |
| Mar 31 2023 | n/a | n/a | -US$719m |
| Dec 31 2022 | US$12m | US$796k | -US$707m |
| Sep 30 2022 | n/a | n/a | -US$678m |
| Jun 30 2022 | n/a | n/a | -US$506m |
| Mar 31 2022 | n/a | n/a | -US$470m |
| Dec 31 2021 | US$10m | US$769k | -US$454m |
| Sep 30 2021 | n/a | n/a | -US$356m |
| Jun 30 2021 | n/a | n/a | -US$351m |
| Mar 31 2021 | n/a | n/a | -US$204m |
| Dec 31 2020 | US$5m | US$759k | -US$187m |
| Sep 30 2020 | n/a | n/a | -US$256m |
| Jun 30 2020 | n/a | n/a | -US$301m |
| Mar 31 2020 | n/a | n/a | -US$425m |
| Dec 31 2019 | US$7m | US$714k | -US$403m |
| Sep 30 2019 | n/a | n/a | -US$397m |
| Jun 30 2019 | n/a | n/a | -US$371m |
| Mar 31 2019 | n/a | n/a | -US$325m |
| Dec 31 2018 | US$5m | US$680k | -US$198m |
| Sep 30 2018 | n/a | n/a | -US$192m |
| Jun 30 2018 | n/a | n/a | -US$183m |
| Mar 31 2018 | n/a | n/a | -US$204m |
| Dec 31 2017 | US$7m | US$638k | -US$302m |
Compensation vs Market: Emil's total compensation ($USD13.08M) is above average for companies of similar size in the US market ($USD8.14M).
Compensation vs Earnings: Emil's compensation has increased whilst the company is unprofitable.
CEO
Emil Kakkis (64 yo)
14.4yrs
Tenure
US$13,077,993
Compensation
Dr. Emil D. Kakkis, M.D., Ph D., is Executive Director of Amlogenyx Inc. Dr. Kakkis has been a Director of Actio Biosciences Inc. since July 2024. He is Venture Advisor of Forge Life Science Partners.He i...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 14.4yrs | US$13.08m | 2.92% $ 148.3m | |
| Executive VP of Corporate Strategy & CFO | less than a year | US$5.94m | no data | |
| Chief Legal Officer & Executive VP of Corporate Affairs | 8.3yrs | US$4.04m | 0.017% $ 845.3k | |
| Chief Quality Operations Officer & Executive VP of Translational Sciences | 9.2yrs | US$4.05m | 0.051% $ 2.6m | |
| Executive VP & Chief Commercial Officer | no data | US$4.07m | 0.025% $ 1.3m | |
| Senior VP | 10.7yrs | no data | 0.019% $ 982.1k | |
| Chief Human Resources Officer & Executive VP | 4yrs | no data | no data | |
| Chief Business Officer & Executive VP | 12.8yrs | US$2.46m | 0.23% $ 11.6m | |
| Senior Vice President of Business Development & Alliance Management | 6.5yrs | no data | no data | |
| Chief Technical Operations Officer and Executive VP of Gene Therapy Research & Development | 9.3yrs | US$4.24m | 0.044% $ 2.2m | |
| Senior Vice President of Corporate Strategy & Finance | no data | no data | no data | |
| Chief Medical Officer & Executive VP | 1.3yrs | no data | 0.020% $ 1.0m |
8.7yrs
Average Tenure
58yo
Average Age
Experienced Management: RARE's management team is seasoned and experienced (8.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 14.4yrs | US$13.08m | 2.92% $ 148.3m | |
| Independent Non-Executive Chairman | 9.4yrs | US$499.89k | 0.023% $ 1.2m | |
| Independent Director | 10.7yrs | US$479.89k | 0.016% $ 820.3k | |
| Independent Director | 5.6yrs | US$466.89k | 0.016% $ 820.3k | |
| Independent Director | 7.4yrs | US$459.89k | 0.021% $ 1.1m | |
| Independent Director | 3.3yrs | US$469.39k | 0.0058% $ 295.0k | |
| Independent Director | 9.6yrs | US$482.39k | 0.023% $ 1.2m | |
| Independent Director | 2.4yrs | US$460.39k | 0.011% $ 583.8k |
8.4yrs
Average Tenure
63yo
Average Age
Experienced Board: RARE's board of directors are considered experienced (8.4 years average tenure).